Monkeypox in 2024
Monkeypox, often referred to as Mpox, has been declared a public health emergency of international concern by the World Health Organisation (WHO) due to the rapid spread of its lethal Clade1b strain, with significant health impacts across the African continent.
Mpox spreads through close contact with an infected person, including skin-to-skin contact, respiratory droplets, and contact with contaminated materials3. Symptoms include fever, chills, swollen lymph nodes, exhaustion, muscle aches, and a characteristic rash that can appear anywhere on the body2. The disease can be severe in vulnerable populations that includes children, pregnant women, and those with poor immune systems, with a fatality rate of up to 10%.
There are two main types of mpox strains - Clade 1 and Clade 2. A previous Mpox public health emergency, declared in 2022, was caused by the relatively mild Clade 2. However, this time it is the far more deadly Clade 1 - which has killed up to 10% of those getting sick in previous outbreaks - that is surging. Mutations have led to an offshoot - called Clade 1b - that has since spread rapidly.
Given the severity of the current outbreak, there is an urgent need for effective diagnostic tools and treatments. It is hoped the declaration of Mpox will lead to research, funding, and the escalation of other international public health measures to contain the outbreak.
2BScientific Limited are committed to supporting the research community by providing high quality antibodies, Mpox virus recombinant proteins, Mpox PCR detection kits and Elisa Kits and Mpox Virus Protein Arrays that can help towards getting a deeper understanding of the virus and its behaviour.
https://www.2bscientific.com/products?product=monkeypox
| Products | |
|---|---|
| Mpox PCR Detection Kit | Mpox Recombinant Proteins |
| Mpox Elisa Kit | Mpox Virus Protein Assay |
For more information on our range of Monkeypox products and how they can support your research, follow the links above or contact our team of experts.